At present, most decisions concerning the use of adjuvant therapy in lymph node-negative breast cancer patients are made on the basis of traditional factors such as tumor size, nodal status, and histopathologic features. However, prognostic factors are being investigated that could identify high-risk groups and that could better address treatment efforts for those patients. Identification of more accurate prognostic markers, such as the expression of the mutant p53 protein encoded by the p53 (also known as TP53) tumor suppressor gene, that are reproducible, easily assessable, and independent in predicting clinical outcome would have a beneficial impact on cancer treatment decisions.
|Titolo:||p53 as an independent prognostic marker in lymph node-negative breast cancer patients|
|Parole Chiave:||Regression Analysis; Odds Ratio; Analysis of Variance; Tumor Suppressor Protein p53; Humans; Retrospective Studies; Prognosis; Breast Neoplasms; Likelihood Functions; Multivariate Analysis; Survival Rate; Genes, p53; Tritium; Logistic Models; Risk Factors; Adult; Middle Aged; Neoplasm Recurrence, Local; Tumor Markers, Biological; Immunohistochemistry; Female; Menopause; Survival Analysis; Receptors, Estrogen|
|Settore Scientifico Disciplinare:||Settore MED/01 - Statistica Medica|
|Data di pubblicazione:||16-giu-1993|
|Digital Object Identifier (DOI):||10.1093/jnci/85.12.965|
|Appare nelle tipologie:||01 - Articolo su periodico|